Table 2.

Univariate analysis of prognostic factors for patients with locally advanced rectal carcinoma

Variable	OS			DFS			LRFS			DMFS
	HR	p value	95 % CI	HR	p value	95 % CI	HR	p value	95 % CI	HR	p value	95 % CI
Pathological stage
ypT0–2N0	1			1			1			1
ypT3–4N0	2.076	0.074	0.933–4.622	1.031	0.925	0.547–1.942	1.279	0.508	0.617–2.651	1.519	0.317	0.670–3.444
ypT0–4N+	3.688	0.001	1.702–7.911	2.255	0.007	1.246–4.081	2.816	0.003	1.429–5.546	3.429	0.002	1.602–7.339
pT stage
ypT3–4 vs. ypT0–2	3.131	0.001	1.578–6.212	1.675	0.049	1.001–2.801	1.970	0.025	1.090–3.561	2.615	0.005	1.328–5.150
pN stage
ypN+ vs. ypN0	2.595	0.002	1.414–4.760	2.252	0.004	1.333–3.804	2.519	0.002	1.411–4.498	2.889	0.001	1.540–5.420
Sex
Female vs. Male	0.950	0.879	0.488–1.850	0.943	0.838	0.539–1.652	0.894	0.730	0.473–1.690	1.060	0.867	0.538–2.087
Age, years
>56 vs. ≤56	1.243	0.477	0.682–2.266	1.243	0.396	0.752–2.056	1.433	0.215	0.812–2.532	1.444	0.248	0.774–2.695
Pretreatment CEA level, μg/L
≥5.0 vs. <5.0	0.868	0.648	0.474–1.592	0.941	0.816	0.566–1.565	1.145	0.640	0.650–2.018	1.282	0.434	0.689–2.385
Pretreatment Hb level, g/L
Anemia vs. normal	1.092	0.815	0.521–2.289	1.047	0.888	0.554–1.976	1.225	0.558	0.622–2.412	1.020	0.960	0.469–2.220
Distance btw anal verge and lower edge of tumor, cm
≤5.0 vs. >5.0	1.294	0.429	0.683–2.449	1.643	0.082	0.939–2.877	5.446	0.023	1.257–23.586	0.907	0.761	0.481–1.707
Differentiation of tumor
Well–vs. poorly differentiated	1.315	0.126	0.926–1.869	1.198	0.246	0.883–1.624	1.124	0.519	0.788–1.601	1.198	0.345	0.823–1.744
cT stage
cT4 vs. cT1–3	1.837	0.074	0.943–3.577	1.856	0.030	1.060–3.249	1.735	0.083	0.931–3.233	1.648	0.148	0.838–3.241
cN stage
cN+ vs. cN0	1.291	0.444	0.671–2.484	1.107	0.712	0.646–1.897	1.150	0.654	0.624–2.121	1.473	0.278	0.732–2.966
Post–op adjuvant chemotherapy
Yes vs. None	1.712	0.089	0.921–3.181	1.614	0.074	0.955–2.726	0.792	0.122	0.589–1.065	1.687	0.110	0.888–3.207